Tags

Type your tag names separated by a space and hit enter

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Diabetes Res Clin Pract. 2005 Jul; 69(1):5-13.DR

Abstract

OBJECTIVE

To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters.

STUDY DESIGN AND METHODS

91 type 2 diabetic patients with the metabolic syndrome participated. All patients took a fixed dose of glimepiride, 4 mg/day. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) in a randomized, controlled, double-blind clinical study. We compared body mass index (BMI), glycemic control, coagulation and fibrinolysis parameters, and heart rate (HR) during 12 months of this treatment.

RESULTS

A total of 87 completed the study (pioglitazone n=45 or rosiglitazone n=42). Body mass index increased after 12 months compared to baseline (p<0.05) in both groups. A significant decrease in glycated haemoglobin (HbA(1c)) was observed after 9 (p<0.05), and 12 (p<0.01) months in both groups. After 9 and 12 months, mean fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were lower in both groups (p<0.05 and 0.01, respectively), as were fasting plasma insulin (FPI) and postprandial plasma insulin (PPI) (p<0.05 and p<0.01, respectively). An improvement in the homeostasis model assessment index (HOMA index) was seen at 9 and 12 months (p<0.05 and 0.01, respectively) compared to the baseline value in both groups. Plasminogen activator inhibitor 1 (PAI-1) was significant lower (p<0.05) in both groups after 12 months compared to the baseline values. No changes in tissue-plasminogen activator (t-PA) and fibrinogen (Fg) were seen during the study nor were there any changes in transaminases.

CONCLUSIONS

We conclude that the addition of a thiazolinedione to glimepiride treatment in type 2 diabetic subjects with the metabolic syndrome is associated with a slight but significant reduction of PAI-1 value, related to a similar reduction in insulinresistance.

Authors+Show Affiliations

Department of Internal Medicine and Therapeutics, University of Pavia, P.le C. Golgi, 2 - 27100 Pavia, Italy. giuderosa@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15955382

Citation

Derosa, Giuseppe, et al. "A Comparison of the Effects of Pioglitazone and Rosiglitazone Combined With Glimepiride On Prothrombotic State in Type 2 Diabetic Patients With the Metabolic Syndrome." Diabetes Research and Clinical Practice, vol. 69, no. 1, 2005, pp. 5-13.
Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69(1):5-13.
Derosa, G., Cicero, A. F., Gaddi, A., Ragonesi, P. D., Piccinni, M. N., Fogari, E., Salvadeo, S., Ciccarelli, L., & Fogari, R. (2005). A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Research and Clinical Practice, 69(1), 5-13.
Derosa G, et al. A Comparison of the Effects of Pioglitazone and Rosiglitazone Combined With Glimepiride On Prothrombotic State in Type 2 Diabetic Patients With the Metabolic Syndrome. Diabetes Res Clin Pract. 2005;69(1):5-13. PubMed PMID: 15955382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. AU - Derosa,Giuseppe, AU - Cicero,Arrigo F G, AU - Gaddi,Antonio, AU - Ragonesi,Pietro D, AU - Piccinni,Mario N, AU - Fogari,Elena, AU - Salvadeo,Sibilla, AU - Ciccarelli,Leonardina, AU - Fogari,Roberto, Y1 - 2004/12/29/ PY - 2004/05/21/received PY - 2004/10/15/revised PY - 2004/10/27/accepted PY - 2005/6/16/pubmed PY - 2005/10/27/medline PY - 2005/6/16/entrez SP - 5 EP - 13 JF - Diabetes research and clinical practice JO - Diabetes Res Clin Pract VL - 69 IS - 1 N2 - OBJECTIVE: To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters. STUDY DESIGN AND METHODS: 91 type 2 diabetic patients with the metabolic syndrome participated. All patients took a fixed dose of glimepiride, 4 mg/day. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) in a randomized, controlled, double-blind clinical study. We compared body mass index (BMI), glycemic control, coagulation and fibrinolysis parameters, and heart rate (HR) during 12 months of this treatment. RESULTS: A total of 87 completed the study (pioglitazone n=45 or rosiglitazone n=42). Body mass index increased after 12 months compared to baseline (p<0.05) in both groups. A significant decrease in glycated haemoglobin (HbA(1c)) was observed after 9 (p<0.05), and 12 (p<0.01) months in both groups. After 9 and 12 months, mean fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were lower in both groups (p<0.05 and 0.01, respectively), as were fasting plasma insulin (FPI) and postprandial plasma insulin (PPI) (p<0.05 and p<0.01, respectively). An improvement in the homeostasis model assessment index (HOMA index) was seen at 9 and 12 months (p<0.05 and 0.01, respectively) compared to the baseline value in both groups. Plasminogen activator inhibitor 1 (PAI-1) was significant lower (p<0.05) in both groups after 12 months compared to the baseline values. No changes in tissue-plasminogen activator (t-PA) and fibrinogen (Fg) were seen during the study nor were there any changes in transaminases. CONCLUSIONS: We conclude that the addition of a thiazolinedione to glimepiride treatment in type 2 diabetic subjects with the metabolic syndrome is associated with a slight but significant reduction of PAI-1 value, related to a similar reduction in insulinresistance. SN - 0168-8227 UR - https://www.unboundmedicine.com/medline/citation/15955382/A_comparison_of_the_effects_of_pioglitazone_and_rosiglitazone_combined_with_glimepiride_on_prothrombotic_state_in_type_2_diabetic_patients_with_the_metabolic_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(04)00346-8 DB - PRIME DP - Unbound Medicine ER -